Uganda declared Ebola virus disease outbreak
On Sept. 20, 2022, The health authorities in Uganda declared an outbreak of Ebola after a case of…
-
-
Novavax Nuvaxovid COVID-19 vaccine received expanded EUA in Taiwan for use in adolescents aged 12 through 17
On Sept. 16, 2022, Novavax announced that the Taiwan Food and Drug Administration had granted expanded emergency use…
-
Novavax Nuvaxovid COVID-19 vaccine became available in Israel for individuals aged 12 and older
On Sept. 16, 2022, Novavax announced that the Israel Ministry of Health had granted an import and use…
-
Novavax and Serum Institute of India announced full product registration in South Africa of Novavax COVID-19 vaccine
On Sept. 13, 2022, Novavax and Serum Institute of India, the world’s largest vaccine manufacturer by volume, announced…
-
Patient with HIV achieved remission following stem cell transplant
On Jul. 27, 2022, City of Hope announced that a 66-year-old man who was diagnosed with HIV in…
-
Aegis Sciences begin Mpox testing, increasing nationwide testing capacity
On Jul 14. 2022, Aegis Sciences announced it is was authorized to begin testing for mpox using the…
-
Benaroya Research Institute received $11.4 million to explore link between viruses and immune system diseases
On Jun. 17, 2022, Benaroya Research Institute at Virginia Mason (BRI) announced a 5-year, $11.4 million grant from…
-
Sorrento announced COVISHIELD antibody nasal drops prevent productive SARS-CoV-2 infections
On Mar. 2, 2022, Sorrento Therapeutics announced that new preclinical results demonstrated that pretreating an animal with intranasal…
-
Health Canada authorized Novavax COVID-19 vaccine
On Feb. 17, 2022, Novavax announced that Health Canada had granted authorization for Nuvaxovid COVID-19 Vaccine (Recombinant protein,…
-
CDC announced H5N1 bird flu virus in U.S. wild birds and poultry posed a low risk to the public
On Feb. 14, 2022, The U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspective Service (APHIS) announced…
-
Data suggested sotrovimab retained neutralizing activity against Omicron subvariant BA.2
On Feb. 10, 2022, Vir Biotech announced that preclinical data suggested that sotrovimab, an investigational monoclonal antibody authorized…
-
Research scientists identified vulnerable site on multiple coronaviruses that could be targeted to prevent future pandemics.
On Feb. 10, 2022, Scripps Research announced that the COVID-causing virus SARS-CoV-2 harbors a vulnerable site at the…
-
NIH-funded study suggested COVID-19 increased risk of pregnancy complications
On Feb. 4, 2022, the NIH announced a study that showed pregnant women with COVID-19 appeared to be…
-
Cocrystal Pharma selected two lead antiviral drug candidates for COVID-19 oral drug program
On Jan. 27, 2022, Cocrystal Pharma announced that it had selected two investigational novel antiviral drug candidates for further…
-
Hyperimmune intravenous immunoglobulin does not improve outcomes for adults hospitalized with COVID-19
On Jan. 27, 2022, NIAID announced that a clinical trial found that the combination of remdesivir plus a…
-
Report published in PNAS detailed spread and evolution of SARS-CoV-2 in white-tailed deer across the U.S.
On Jan. 25. 2022, a report published in PNAS provided strong evidence of extensive SARS-CoV-2 infection of white-tailed…
-
Mixed vaccine schedules offered strong booster responses after two doses of CoronaVac vaccine
On Jan. 24, 2022, the University of Oxford announced that a third booster dose of either the ChAdOx1…
-
Anixa Biosciences and MolGenie announced early potency analysis of SARS-CoV-2 protease inhibitor
On Jan. 24, 2022, Anixa Biosciences announced that the company and its partner, MolGenie, had synthesized a compound…
-
Biotechnology | COVID-19 | NIH | Therapeutics
‘Ultrapotent’ antibodies neutralized SARS-CoV-2 variants in NIAID study
On Jan. 20, 2022, scientists from the National Institute of Allergy and Infectious Diseases (NIAID) announced that they…
-
Australia Therapeutic Goods Administration granted provisional registration for Novavax COVID-19 vaccine
On Jan. 19, 2022, Novavaxa announced that Australia’s Therapeutic Goods Administration had granted approval for provisional registration of…
-
USDA confirmed highly pathogenic avian influenza in a wild bird in South Carolina
On Jan. 14, 2022, the U.S. Department of Agriculture’s (USDA) National Veterinary Services Laboratories confirmed a highly pathogenic…
-
U.S. FDA authorizd InteliSwabﾙ COVID-19 rapid tests for at-home testing for delta variant detection
On Jan. 13, 2022, OraSure Technologies that its InteliSwabﾮ COVID-19 rapid tests detected the Omicron variant as effectively…
-
CDC study showed flu vaccination prevented severe flu Illness in U.S. children
On Jan. 13, 2022, the Centers for Disease Control and Prevention announced a study published in the journal…
-
Pfizer and BioNTech signed global collaboration agreement to develop first mRNA-based shingles vaccine
On Jan. 5, 2022, Pfizer and BioNTech announced a new research, development and commercialization collaboration to develop a…
-
Hologic added Aptima SARS-CoV-2 assay to its Global Access Initiative in resource-limited countries
On Jan 5, 2022, Hologic the addition of the Aptimaﾮ SARS-CoV-2 assay to its Global Access Initiative, a…
-
Revelar Biotherapeutics and Twist Bioscience announced RBT-0813 neutralized SARS-CoV-2 Omicron and Delta variants
On Jan 5, 2022, Revelar Biotherapeutics and Twist Bioscience announced that RBT-0813 binded to and neutralized the Omicron…
-
Biotechnology | COVID-19 | Disease | Genomics
PacBio’s HiFiViral Surveillance Kit Performance not impacted by Omicron mutations
On Dec. 28, 2021, Pacific Biosciences announced that its new HiFiViral SARS-CoV-2 solution had successfully sequenced and captured…
-
Development of WRAI’s pan-coronavirus vaccine showed promise
On Dec. 28, 2021, researchers at the Walter Reed Army Institute of Research in Silver Spring, Maryland announced…
-
Sorrento announced COVISTIX COVID-19 virus rapid antigen detection test detected the Omicron variant
On Dec. 27, 2021, Sorrento Therapeutics announced that initial testing of COVISTIX on recombinant N proteins demonstrated its…
-
Biotechnology | COVID-19 | FDA | Medicine | Pharmaceutical | Therapeutics
Merck and Ridgeback’s molnupiravir received U.S. FDA EUA for treatment of high-risk adults with COVID-19
On Dec. 23, 2021, Merck and Ridgeback Biotherapeutics announced that the U.S. Food and Drug Administration (FDA) had…
